Immunotherapy after chemo may keep High-Risk lymphoma at bay
NCT ID NCT03463057
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent relapse in people with high-risk diffuse large B-cell lymphoma. About 109 adults who achieved complete remission after initial treatment received atezolizumab as a consolidation therapy. The goal is to see if this approach improves disease-free survival by clearing any remaining cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BE-Antwerpen Edegem-UZA
Antwerp, Belgium
-
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
-
BE-Brugge-AZBRUGGE
Bruges, Belgium
-
BE-Leuven-UZLEUVEN
Leuven, Belgium
-
BE-Roeselare-AZDELTA
Roeselare, Belgium
-
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
-
NL-Amsterdam-OLVG
Amsterdam, Netherlands
-
NL-Amsterdam-VUMC
Amsterdam, Netherlands
-
NL-Apeldoorn-GELREAPELDOORN
Apeldoorn, Netherlands
-
NL-Breda-AMPHIA
Breda, Netherlands
-
NL-Delft-RDGG
Delft, Netherlands
-
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
-
NL-Den Haag-HAGA
The Hague, Netherlands
-
NL-Dordrecht-ASZ
Dordrecht, Netherlands
-
NL-Ede-ZGV
Ede, Netherlands
-
NL-Eindhoven-CATHARINA
Eindhoven, Netherlands
-
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
-
NL-Enschede-MST
Enschede, Netherlands
-
NL-Groningen-UMCG
Groningen, Netherlands
-
NL-Hilversum-TERGOOI
Hilversum, Netherlands
-
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
-
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
-
NL-Leiden-LUMC
Leiden, Netherlands
-
NL-Maastricht-MUMC
Maastricht, Netherlands
-
NL-Nieuwegein-ANTONIUS
Nieuwegein, Netherlands
-
NL-Nijmegen-CWZ
Nijmegen, Netherlands
-
NL-Rotterdam-ERASMUSMC
Rotterdam, Netherlands
-
NL-Rotterdam-MAASSTADZIEKENHUIS
Rotterdam, Netherlands
-
NL-Sittard-Geleen-ZUYDERLAND
Sittard, Netherlands
-
NL-Tilburg-ETZ
Tilburg, Netherlands
-
NL-Utrecht-UMCUTRECHT
Utrecht, Netherlands
-
NL-Zwolle-ISALA
Zwolle, Netherlands
Conditions
Explore the condition pages connected to this study.